[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100473890":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":38,"locations":25,"responsibleParty":48,"collaborators":50,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":25,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":25,"overallStatus":77,"whyStopped":25,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":85,"locationsCount":25},{"fullName":5,"class":6},"ANRS, Emerging Infectious Diseases","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HIV+ GROUP","ACTIVE_COMPARATOR","Subjects included in the ANRS EP 46 NOVAA trial:\n\n• 40 HIV positive subjects from consultations for infectious diseases and travel medicine centers at Saint-Louis, Cochin-Pasteur and Bichat hospitals (on HAART for at least one year and not modified in the 3 months preceding the pre-inclusion visit, CD4 \\> 350\u002Fmm3 and a viral load \\\u003C50 copies \u002F mL for at least 6 months).",[13],"Biological: Yellow fever vaccination (STAMARIL)",{"label":15,"type":16,"description":17,"interventionNames":18},"HIV- GROUP","OTHER","Subjects included in the ANRS EP 46 NOVAA trial:\n\n• 20 HIV negative subjects from the consultation of travelers from Saint-Louis, Bichat and Cochin-Pasteur hospitals.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","Yellow fever vaccination (STAMARIL)","Yellow fever vaccination (STAMARIL) for HIV positive and negative subjects",[9,15],null,[27,31,35],{"name":28,"affiliation":29,"role":30},"Nathalie COLIN de VERDIERE","Maladies Infectieuses St Louis Paris","STUDY_DIRECTOR",{"name":32,"affiliation":33,"role":34},"Odile LAUNAY","CIC Cochin Paris","PRINCIPAL_INVESTIGATOR",{"name":36,"affiliation":37,"role":34},"Jade GHOSN","Hôpital Bichat Paris",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":25,"email":43},"Nathalie COLIN DE VERDIERE","CONTACT","01.42.02.66.45","nathalie.colin-de-verdiere@aphp.fr",{"name":45,"role":41,"phone":46,"phoneExt":25,"email":47},"Vincent MEIFFREDY","01.45.59.52.06","vincent.meiffredy@inserm.fr",{"type":49,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[51,53,55],{"name":52,"class":16},"Saint-Louis Hospital, Paris, France",{"name":54,"class":16},"Bichat Hospital",{"name":56,"class":16},"Hôpital Cochin","100473890","immunity-to-yellow-fever-in-hiv-infected-patients-10-years-after-a-primary-anti-yellow-fever-vaccination-100473890",false,"NCT05450770","Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination","The Yellow Fever Vaccine Immunity in HIV Infected Patients: Studies of Immunological Responses at 10 Years (ANRS 0146s NovaaTen)","Inclusion Criteria:\n\n* Subjects included in the ANRS EP 46 NOVAA trial:\n\n  * 40 HIV positive subjects from consultations for infectious diseases and travel medicine centers at Saint-Louis, Cochin-Pasteur and Bichat hospitals (on HAART for at least one year and not modified in the 3 months preceding the pre-inclusion visit, CD4 \\> 350\u002Fmm3 and a viral load \\\u003C50 copies \u002F mL for at least 6 months).\n  * 20 HIV negative subjects from the consultation of travelers from Saint-Louis, Bichat and Cochin-Pasteur hospitals.\n  * Subjects agreeing to be monitored according to the terms of the protocol.\n  * Subjects affiliated to a Social Security scheme or beneficiaries of such a scheme.\n  * Signature of informed consent.\n\nExclusion Criteria:\n\n* Non-volunteers for the 10-year follow-up\n* Subject under curatorship, guardianship or safeguard of justice.",true,"ALL","18 Years",{"count":68,"type":69},60,"ESTIMATED","INTERVENTIONAL",[72],"NA","ANRS 0146s NovaaTen study aims to determine the vaccine responses in the participants of the ANRS EP46 Novaa trial 10 years after a primary anti-yellow fever vaccination",[75,76],"HIV Infections","Yellow Fever","NOT_YET_RECRUITING","2024-07-29",{"date":80,"type":81},"2024-07-30","ACTUAL",{"date":83,"type":69},"2024-11-01",{"date":83,"type":69},{"name":5,"class":6}]